Intellijoint Surgical Inc., a medical technology company co-founded by Waterloo Engineering graduates, announced today that it has been given US Food and Drug Administration clearance for the next generation of intellijoint HIP™ - the company's flagship product initially developed as a Capstone Design project.
intellijoint HIP™ - a miniature surgical smart tool used by surgeons to improve accuracy during hip replacement surgery was developed at the University of Waterloo by Armen Bakirtzian (University of Toronto graduate), Richard Fanson (BASc mechatronics '08, MASc, electrical and computer engineering '10) and Andre Hladio (BASc mechatronics '08, MASc, electrical and computer engineering '10). After graduation, the team co-founded Intellijoint Surgical Inc., obtained a Health Canada license and FDA clearance, and saw the first surgery performed using the device in 2015.
Since then, intellijoint HIP™ has been used in hundreds of procedures across North America and the company looks to expand following the launch of the newest upgrade of intellijoint HIP™; which now provides cup position (inclination and anteversion), in addition to the original leg length, offset, and change in hip center measurements.
intellijoint HIP™ can assist in the prevention of recurrent instability, hip dislocation and leg length discrepancy and may expedite decision-making and improve accuracy in achieving preoperative planned targets, ultimately improving patient satisfaction and healthcare economics.
Intellijoint's core technology represents the latest in miniature 3D surgical measurement within the sterile field. intellijoint HIP™ is the first of many products to benefit from this new novel core technology. It is safe, fast, accurate, and precise. intellijoint HIP's compatibility with the majority of implant vendors, paired with its cost-effectiveness, opens accessibility of computer-assisted surgery to all orthopaedic surgeons.